

## Genotypic detection of multidrug resistant *Mycobacterium tuberculosis* strains

DOI: 10.26327/RBL2018.233

Received for publication, September, 23, 2016

Accepted, October, 9, 2017

CĂTĂLINA LUNCĂ<sup>1,2</sup>, OLIVIA SIMONA DORNEANU<sup>1,3\*</sup>, DANIELA DICULENCU<sup>4</sup>,  
TEODORA VREMERĂ<sup>1,2</sup>, LUMINIȚA SMARANDA IANCU<sup>1,2</sup>

<sup>1</sup>“Grigore T. Popa” University of Medicine and Pharmacy, Microbiology Department, Iași, Romania

<sup>2</sup> National Institute of Public Health – Regional Centre for Public Health, Iași, Romania

<sup>3</sup>“St. Parascheva” Clinical Hospital of Infectious Diseases, Iași, Romania

<sup>4</sup> Clinical Hospital of Pulmonology Iași, Romania

\*Address for correspondence to: [odorneanu@yahoo.com](mailto:odorneanu@yahoo.com)

### Abstract

Multidrug-resistant *Mycobacterium tuberculosis* strains can now be rapidly detected using genetic methods. Most mutations that induce resistance to rifampicin and isoniazid appear in the core region of *rpoB* gene and, respectively, in codon 315 of *katG* gene and in the promoter region *mabA-inhA*:-15. Our objective was the assessment of cost and test performance of multiplex allele-specific polymerase chain reaction (MAS-PCR) for the detection of mutations that induce rifampicin and isoniazid resistance in *M. tuberculosis*. We have analyzed 83 non-duplicate *M. tuberculosis* isolates using conventional phenotypic drug susceptibility testing and a single-step MAS-PCR assay for simultaneous detection of mutations in codons 531, 526 and 516 of *rpoB* gene, as well as in codon 315 of *katG* and in the promoter region *mabA-inhA*:-15. We have calculated the cost of genotypic testing/strain. MAS-PCR technique detected rifampicin resistance with 88.88% sensitivity and 100% specificity in comparison to phenotypic testing, while isoniazid resistance was detected with 95.06% sensitivity and 100% specificity. The cost of genotypic testing/strain was approximately US\$ 1.62. MAS-PCR technique demonstrated good sensitivity and specificity for detection of mutations that induce rifampicin and isoniazid resistance, and therefore can be used as a rapid and inexpensive method for diagnosis of multidrug resistant tuberculosis.

**Keywords:** resistance, rifampicin, isoniazid, MAS-PCR, cost.

### 1. Introduction

Tuberculosis (TB) is a major worldwide public health issue and the emergence of drug-resistant strains poses a great concern for the control of this disease. Multidrug-resistant tuberculosis (MDR-TB) is defined by resistance to at least rifampicin (RIF) and isoniazid (INH). These strains are spreading worldwide and can acquire additional resistance to fluoroquinolones and one of the three injectable drugs: capreomycin, kanamycin or amikacin becoming extensively drug-resistant (XDR-TB). Difficulties in MDR-TB detection contribute to the dissemination of these strains, since conventional drug susceptibility testing is time-consuming, costly and poses technical challenges. New molecular biology techniques allow for rapid diagnosis and could represent a solution to those problems, improving the management of MDR-TB cases.

According to World Health Organization Global TB report 2015, MDR-TB accounted for 3.3% of new TB cases and 20% of previously treated cases worldwide. In 2014 there were 300,000 estimated MDR-TB cases among notified pulmonary cases but only 41% of them were detected (123,000) (WORLD HEALTH ORGANIZATION [1]). In Romania, the TB incidence and prevalence rates were estimated at 81 per 100,000 populations (71-91%000) and 99 per 100,000 populations (41-184%000), respectively. These were the highest values for TB incidence and prevalence rates in the European Union/European Economic Area countries in 2014 (ECDC/WHO REGIONAL OFFICE FOR EUROPE [2]). In our country,

MDR-TB represented 2.8% of notified new TB cases and 11% of notified previously treated TB cases. The number of estimated MDR-TB cases among notified pulmonary TB cases was 650 and 578 of them (89%) were confirmed (WORLD HEALTH ORGANIZATION [1]). In this situation, the revision of diagnosis algorithm in order to improve the cost-benefit ratio and to support patients' treatment, especially for MDR-TB cases, becomes a crucial objective.

Our objective was to evaluate the opportunity of using molecular techniques for rapid detection of MDR-TB strains in routine diagnosis. To reach this objective, we have analyzed the performance parameters of MAS-PCR technique (sensitivity, specificity, accuracy) for detection of RIF and INH resistance and identification of MDR strains, in comparison to conventional phenotypic drug susceptibility testing. We have also calculated the cost of genetic testing/strain.

## 2. Materials and Methods

### *Selected strains*

The study included a collection of 83 non-duplicate *Mycobacterium tuberculosis* strains from the Bacteriology Laboratory of the Clinical Hospital of Pulmonology Iasi, isolated from patients with pulmonary TB between January 2008 and December 2012.

### *Drug susceptibility testing (DST)*

We used conventional phenotypic testing (proportion method) on Löwenstein-Jensen medium for antibiotic susceptibility to first line antituberculous drugs (G. CANETTI & al. [3]; G. CANETTI & al. [4]; S.J. KIM [5]). Reference strain *M. tuberculosis* H37Rv ATCC 27294 was used as control.

### *DNA extraction procedure*

DNA extraction was done using a method previously described (C. CAVASOGLU & al. [6]) and modified: a 2 McFarland culture suspension of *M. tuberculosis* was inactivated by boiling for 20 min, followed by sonication for 15 min and centrifugation for 5 min at 14000 rpm. DNA yield in the supernatant was determined by spectrophotometry using NanoPhotometer® P 300 (Implen GmbH, Germany).

### *MAS-PCR*

For the molecular detection of RIF and INH resistance we have applied a single-step multiplex allele-specific PCR, which allowed the simultaneous detection of mutations in codons 531, 526 and 516 of *rpoB* gene and in codon 315 of *katG* gene, as well as in promoter region *mabA-inhA*:-15. We used the Corbett Palm-Cycler (*Qiagen*, SUA) and primers synthesized by Eurogentec (*Eurogentec* S.A., Liège, Belgium) (Table 1).

**Table 1.** Description of primers for MAS-PCR

Genes	Primer	Sequence (5'-3')	Size (bp)	References
<i>rpoB</i>	<i>RIR</i>	TGA CCC GCG CGT ACA C		I. MOKROUSOV & al. [7]
	<i>R531B</i>	ACA AGC GCC GAC TGT C	167	
	<i>R526B</i>	GTC GGG GTT GAC CCA	181	
	<i>R516B</i>	GCT GAG CCA ATT CAT GGA	214	
<i>katG</i>	<i>katGOF</i>	GCA GAT GGG GCT GAT CTA CG		I. MOKROUSOV & al. [8]
	<i>katG5R</i>	ATA CGA CCT CGA TGC CGC	292	
<i>mabA-inhA</i> :-15	<i>InhAPF2</i>	CAC CCC GAC AAC CTA TCG		Z. ALLEGUI & al. [9]
	<i>InhAP15</i>	GCG CGG TCA GTT CCA CA	270	

Each PCR reaction had a final volume of 50 µl and included: template DNA (4 µl), *RIR* (500 pmol), *R531B* (300 pmol), *R526B* and *R516B* (200 pmol each), *katGOF*, *katG5R*, *InhAPF2*, *InhAP15* (10 pmol each), 1× *ImmoMix*<sup>TM</sup> Red Master Mix (*Bioline GmbH*, Germany) (25µL), *nuclease-free water* (5 µl). PCR amplification was carried out according to the protocol described by Allegui *et al.* (Z. ALLEGUI & al. [9]) and modified: initial denaturation 3 min at 96°C, followed by 23 cycles as follows: 50 s at 95°C, 40 s at 63°C and 1 min at 72°C, with a final extension of 7 min at 72°C. Reference strain *M. tuberculosis* H37Rv ATCC 27294 represented the control for amplification. Each reaction was performed in triplicate. Analysis of amplification products was done by electrophoresis in 2.5% agarose gel. The absence of amplification signified mutation in analyzed codon.

#### *The cost of genotypic testing / strain*


We have calculated the cost of testing/strain depending on the acquisition price of reagents for MAS-PCR (primers, master mix, nuclease-free water) and electrophoresis (agarose, buffer solution, ethidium bromide). All prices included VAT 20%. The cost did not include the expenses for infrastructure, equipment, consumables and staff (training and salaries).

#### *Statistical analysis*

Statistical analysis was performed using Epi Info<sup>TM</sup>. A p-value of less than 0.05 was considered significant.

### 3. Results and discussion

In our study, the phenotypic testing of resistance to first line antituberculous drugs showed that, of the total 83 strains, 80 were MDR (96.38%), one strain had monoresistance to RIF (1.2%), and one to INH (1.2%), while one strain was sensitive to first line antituberculous drugs (1.2%). The rates of resistance to first line antituberculous drugs are summarized in Figure 1.



**Figure 1.** The results for DST on Löwenstein-Jensen medium for first line antituberculous drugs

MAS-PCR technique detected RIF resistance in 72 strains, with a sensitivity of 88.88% (81-95%, a 95% confidence interval, p=0.0002). The specificity of MAS-PCR in detecting RIF resistance was 100%, the positive predictive value was 100%, and the test accuracy was 89.15% (Table 2).

**Table 2.** MAS-PCR results for detection of RIF resistance, compared with DST results

Test		DST (No. of strains)		Total (No. of strains)
		Resistant	Sensitive	
MAS-PCR (No. of strains)	Resistant	72	0	72
	Sensitive	9	2	11
Total (No. of strains)		81	2	83

The mutations responsible for INH resistance were detected in 77 strains, MAS-PCR technique showing a sensitivity of 95.06% (90-99%, a 95% confidence interval,  $p=0.0000003$ ), specificity of 100%, positive predictive value of 100%, and test accuracy of 95.18% (Table 3).

**Table 3.** MAS-PCR results for detection of INH resistance, compared with DST results

Test		DST (No. of strains)		Total (No. of strains)
		Resistant	Sensitive	
MAS-PCR (No. of strains)	Resistant	77	0	77
	Sensitive	4	2	6
Total (No. of strains)		81	2	83

Of the 80 MDR-TB strains, MAS-PCR technique identified 71 strains, with a sensitivity of 88.75% (80-95%, a 95% confidence interval,  $p=0.00001$ ). Positive predictive value was 100%, and test accuracy was 89.15% (Table 4).

**Table 4.** MAS-PCR results in detection of MDR-TB compared with DST results

Test		DST (No. of strains)		Total (No. of strains)
		Resistant	Sensitive	
MAS-PCR (No. of strains)	Resistant	71	0	71
	Sensitive	9	3	12
Total (No. of strains)		80	3	83

Our results were comparable with those reported by studies that have been conducted in different countries and geographical regions.

In a study by Gupta *et al.* (India), the sensitivity of MAS-PCR technique was 93% for detection of RIF resistance and 83% for detection of INH resistance, with 100% specificity and positive predictive values in detection of each type of resistance. The accuracy of the test was 98% for RIF resistance detection and 94% for INH resistance detection, when compared to DST (A. GUPTA & al. [10]). Another study, conducted in India by Vadwai *et al.*, which compared MAS-PCR performances with DST, reported 94.9% and 89.2% sensitivity of MAS-PCR technique for detection of RIF resistance and INH resistance, respectively. The specificity was 86.9% for detection of RIF resistance and 94% for INH resistance. In the same study, the positive predictive value was 94% for RIF resistance detection and 97.9% for INH resistance detection (V. VADWAI & al. [11]).

In a study by Mohammed *et al.* (Iraq), the sensitivity of MAS-PCR in detecting RIF resistance was 94.5%, while detection of resistance among MDR strains was 90.9%. The INH

resistance was detected in 78.2% of MDR strains. The sensitivity of MAS-PCR in detecting MDR-TB strains was 72.7% (S.H. MOHAMMED & al. [12]), a value lower than in our study (88.75%).

In Central America, Chia *et al.* showed that MAS-PCR detected RIF resistance and INH resistance with 98.4% and 82.8% sensitivity, respectively, while the specificity was 100% versus DST (B.-S. CHIA & al. [13]). These findings were supported by a study conducted in China by Wang and collaborators that showed that MAS-PCR technique had a sensitivity of 97.9% in detecting RIF resistance and 83.3% for INH resistance, with specificities of 100% (X. WANG & al. [14]).

In our study the most frequent mutation associated with RIF resistance appeared in codon 531 of *rpoB* gene (69.13%). The frequencies of mutations in codons 526 and 516 were much lower (11.11% and 8.64%, respectively). No mutations were detected in 9 cases (11.11%). No strain was found to present multiple mutations associated with RIF resistance. INH resistance caused by mutations in codon 315 of *katG* gene had the highest frequency (87.64%). Mutations in promoter region *mabA-inhA* had a frequency of 25.91%. Fifteen strains (18.51%) had simultaneous mutations in *katG315* and *mabA-inhA-15*. The testing showed no mutations in 4 strains.

The same pattern of mutation frequencies was observed in other studies.

In India, several studies have reported frequencies of mutations in codons 531, 526 and 516 of *rpoB* gene between 54.4-67.31%, 15.38-45.29% and 3.85-22.2%, respectively, while the frequency of multiple mutations was between 4.4-19.66% (A. GUPTA & al. [10]; A. GUPTA & al. [15]; R. THIRUMURUGAN & al. [16]). In the same studies, the frequency of mutations in codon 315 of *katG* gene was between 82.95-92.31% (A. GUPTA & al. [10]; A. GUPTA & al. [15]).


Using MAS-PCR assay, Wang and collaborators detected mutations in codons 531, 526 and 516 of *rpoB* gene with frequencies of 79.1%, 14.9% and 5.9%, respectively. Frequencies of mutations in codon 315 *katG* and *mabA-inhA-15* were 68.9% and 19.8%, respectively (X. WANG & al. [14]). Very similar results were obtained by Chia *et al.* who found the following frequencies: 79.1% for 531 *rpoB* mutations, 13.4% for 526 *rpoB* mutations, 6.0% for 516 *rpoB* mutations, 70.1% for 315 *katG* and 19.4% for *mabA-inhA-15* (B.-S. CHIA & al. [13]).

Other studies conducted in Eastern European countries reported frequencies of mutations that induced resistance to INH and RIF similar to our findings (Figure 2).

These results demonstrate that using MAS-PCR technique for highlighting five key mutations that induce resistance to INH and RIF provides good sensitivity in detection of MDR-TB strains.

We have evaluated the cost of MAS-PCR assay at about US\$ 1.62/strain (Table 5). In a study conducted by Tho *et al.*, the cost of MAS-PCR for detection of RIF resistance was about US\$ 1.60 per sample (excluding salary and equipment costs) (D.Q. THO & al. [20]). In another study, Imperiale and collaborators estimated a cost of MAS-PCR of US\$ 14 including staff, overheads and medical supplies (B.R. IMPERIALE & al. [21]).

Our technique had a lower cost than the commercial molecular kits for MDR-TB diagnosis whose costs were estimated between US\$ 50 (D.Q. THO & al. [20]) and US\$ 94 per strip (B.R. IMPERIALE & al. [21]) and also lower than the automated culture methods whose costs were approximately US\$ 10 (S. SOLOMON & al. [22]) to US\$ 31 (B.R. IMPERIALE & al. [21]). In comparison to microscopic observation drug susceptibility assay (US\$ 2) (S. SOLOMON & al. [22]) and DST on Löwenstein-Jensen medium (US\$ 16) (B.R. IMPERIALE & al. [21]), MAS-PCR was less costly.



**Figure 2.** The frequencies of mutations that induce resistance to INH and RIF in Eastern European countries

**Table 5.** The cost of MAS-PCR assay

Steps	Cost / strain* (US\$)
MAS-PCR	1.37
Electrophoresis	0.25
TOTAL	1.62

\*including VAT 20%

Using MAS-PCR assay in MDR-TB detection allowed us to obtain results in 4 hours (amplification and electrophoresis), compared with automated culture methods or microscopic observation drug susceptibility assay which required 7-15 days each (B.R. IMPERIALE & al. [21]; L. SOLARI & al. [23]). Also, MAS-PCR saved approximately 28-41 days in MDR-TB diagnosis compared with DST on Löwenstein-Jensen medium, the gold standard assay (B.R. IMPERIALE & al. [21]).

## 4. Conclusion

MAS-PCR proved to be a low-cost and time-saving technique, with good sensitivity and specificity for detection of mutations that induce resistance to RIF and INH that can be used in the management of MDR-TB cases.

## References

1. WORLD HEALTH ORGANISATION, Global tuberculosis report 2015. [http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1).
2. EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL/WHO REGIONAL OFFICE FOR EUROPE. Tuberculosis surveillance and monitoring in Europe 2016. Stockholm: European Centre for Disease Prevention and Control, 2016. <http://ecdc.europa.eu/en/publications/Publications/ecdc-tuberculosis-surveillance-monitoring-Europe-2016.pdf>.

3. G. CANETTI, S. FROMAN, J. GROSSET, P. HAUDUROY, M. LANGEROVA, H.T. MAHLER, G. MEISSNER, D. A. MITCHISON, L. SULA, Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. *Bull. World Health Organ*, 29: 565- 568 (1963).
4. G. CANETTI, W. FOX, A. KHOMENKO, H.T. MAHLER, N.K. MENON, D.A. MITCHISON, N. RIST, N.A. ŠMELEV, Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. *Bull. World Health Organ*, 41: 21- 43 (1969).
5. S.J. KIM, Drug-susceptibility testing in tuberculosis: Methods and reliability of results, *Eur. Respir. J*, 25: 564-569 (2005).
6. C. CAVUSOGLU, A. TURHAN, P. AKINCI, I. SOYLER, Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in *Mycobacterium tuberculosis* isolates. *J. Clin. Microbiol*, 44(7): 2338- 2342 (2006).
7. I. MOKROUSOV, T. OTTEN, B. VYSHNEVSKIY, O. NARVSKAYA, Allele-specific *rpoB* PCR assays for detection of rifampin-resistant *Mycobacterium tuberculosis* in sputum smears. *Antimicrob. Agents Chemother*, 47(7): 2231- 2235 (2003).
8. I. MOKROUSOV, T. OTTEN, M. FILIPENKO, A. VYAZOVAYA, E. CHRAPOV, E. LIMESCHENKO, L. STEKLOVA, B. VYSHNEVSKIY, O. NARVSKAYA, Detection of isoniazid-resistant *Mycobacterium tuberculosis* strains by a multiplex allele-specific PCR assay targeting *katG* codon 315 variation. *J. Clin. Microbiol*, 40(7): 2509- 2512 (2002).
9. Z. ALLEGUI, A. GHARIANI, H. DRAOUI, A. GHEZAL, E. MEHIRI, L. SLIM-SAIDI, Detection of isoniazid and rifampin resistance of *Mycobacterium tuberculosis* by a multiplex allele-specific polymerase chain reaction (PCR) assay. *Int. J. Mycobacteriol*, 1(1): 34- 39 (2012).
10. A. GUPTA, P. PRAKASH, S.K. SINGH, S. ANUPURBA, Rapid genotypic detection of *rpoB* and *katG* gene mutations in *Mycobacterium tuberculosis* clinical isolates from Northern India as determined by MAS-PCR. *J. Clin. Lab. Anal*, 27(1): 31- 37 (2013).
11. V. VADWAI, A. SHETTY, C. RODRIGUES, Multiplex allele specific PCR for rapid detection of extensively drug resistant tuberculosis. *Tuberculosis (Edinb)*, 92(3): 236- 242 (2012).
12. S.H. MOHAMMED, M.M. AHMED, A.H. AHMED, First experience with using simple polymerase chain reaction-based methods as an alternative to phenotypic drug susceptibility testing for *Mycobacterium tuberculosis* in Iraq. *Int. J. App. Basic. Med. Res*, 3: 98- 105 (2013).
13. B.-S. CHIA, F. LANZAS, D. RIFAT, A. HERRERA, E.Y. KIM, C. SAILER, E. TORRES-CHAVOLLA, P. NARAYANASWAMY, V. EINARSSON, J. BRAVO, J.M. PASCALE, T.R. IOERGER, J.C. SACCHETTINI, P.C. KARAKOUSIS, Use of Multiplex Allele-Specific Polymerase Chain reaction (MAS-PCR) to Detect Multidrug-Resistant Tuberculosis in Panama. *PLoS ONE*, 7(7): e40456. doi: 10.1371/journal.pone.0040456 (2012).
14. X. WANG, J. JIAO, W. XU, X. CHAI, Z. LI, Q. WANG, A simple, rapid and economic method for detecting multidrug-resistant tuberculosis. *Braz. J. Infect. Dis*, 17(6): 667- 671 (2013).
15. A. GUPTA, M.R. NAGARAJA, P. KUMARI, G. SINGH, R. RAMAN, S.K. SINGH, S. ANUPURB, Association of MDR-TB isolates with clinical characteristics of patient from Northern region of India. *Indian J. Med. Microbiol*, 32(3): 270- 276 (2014).
16. R. THIRUMURUGAN, M. KATHIRVEL, K. VALLAYYACHARI, K. SURENDAR, A.V. SAMROT, M. MUTHAIAH, Molecular analysis of *rpoB* gene mutations in rifampicin resistant *Mycobacterium tuberculosis* isolates by multiple allele specific polymerase chain reaction in Puducherry, South India. *J. Infect. Public Health*, 8(6): 619- 625 (2015).
17. V. VALCHEVA, I. MOKROUSOV, O. NARVSKAYA, N. RASTOGI, N. MARKOVA, Molecular snapshot of drug-resistant and drug-susceptible *Mycobacterium tuberculosis* strains circulating in Bulgaria. *Infect. Genet. Evol*, 8(5): 657- 663 (2008).
18. M.A. DYMOVA, O.O. LIASHENKO, P.I. POTEIKO, V.S. KRUTKO, E.A. KHRAPOV, M.L. FILIPENKO, Genetic variation of *Mycobacterium tuberculosis* circulating in Kharkiv Oblast, Ukraine. *BMC Infect. Dis*, 28: 11- 77 (2011).

19. V. CRUDU, E. STRATAN, E. ROMANCENCO, V. ALLERHEILIGEN, A. HILLEMANN, N. MORARU, First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. *J. Clin. Microbiol*, 50(4): 1264- 1269 (2012).
20. D.Q. THO, D.T.M. HA, P.M. DUY, N.T.N. LAN, D.V. HOA, N.V.V. CHAU, J. FARRAR, M. CAWS, Comparison of MDR-TB and GenoType MTBDR assay for the detection of rifampicin-resistant *Mycobacterium tuberculosis*. *Int. J. Tuberc. Lung Dis*, 12(11): 1306- 1312 (2008).
21. B.R. IMPERIALE, A.A. CATALDI, N.S. MORCILLO, Rapid detection of multidrug-resistant *Mycobacterium tuberculosis* by multiplex allele-specific polymerase chain reaction. *Int. J. Tuberc. Lung Dis*, 15(4): 496- 501 (2011).
22. S. SOLOMON, P. BALAKRISHNAN, R. VIGNESH, G. WALDROP, S.S. SOLOMON, K.G. MURUGAVEL, N. KUMARASAMY, T. YEPTHOMI, S. POONGULALI, C.R. SWATHIRAJAN, V. SREENIVASAN, C. CHANDRASEKAR, J. SURIKUMAR, A. MAHILMARAN, G. MANOHARAN, D.A.J. MOORE, A rapid and low-cost microscopic observation drug susceptibility assay for detecting TB and MDR-TB among individuals infected by HIV in South India. *Indian J. Med. Microbiol*, 31: 130- 137 (2013).
23. L. SOLARI, A. GUTIÉRREZ, C. SUÁREZ, O. JAVE, E. CASTILLO, G. YALE, L. ASCENCIOS, N. QUISPE, E. VALENCIA, V. SUÁREZ, [Cost analysis of rapid methods for diagnosis of multidrug resistant tuberculosis in different epidemiologic groups in Perú]. *Rev. Peru Med. Exp. Salud Publica*, 28(3): 426- 431 (2011). [Article in Spanish]